| 新型冠状病毒感染者和灭活疫苗受种者抗体水平研究 |
| |
| 引用本文： | 李东晓, 卢世栋, 胡晓, 宋云, 毋碧聪, 李亚飞, 李懿, 马红霞, 王海峰, 叶莹, 黄学勇. COVID-19确诊病例及灭活疫苗接种者不同时期血清IgA、IgM、IgG抗体检测结果比较[J]. 中国公共卫生, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954 |
| |
| 作者姓名： | 李东晓 卢世栋 胡晓 宋云 毋碧聪 李亚飞 李懿 马红霞 王海峰 叶莹 黄学勇 |
| |
| 作者单位： | 1.河南省疾病预防控制中心，郑州 450016 |
| |
| 基金项目： | 新发传染病监测与预警研究（211100311000）；河南省中青年卫生健康科技创新领军人才培养项目（YXKC2020006）；河南省疫情防控应急科研攻关项目（221111311300）；重大传染病病原体监测、溯源及传播机制研究（221111311300） |
| |
| 摘 要： | 目的 研究不同时期新型冠状病毒感染（COVID-19）病例及接种2019-nCoV灭活疫苗人群的抗体免疫应答规律及特点。 方法 于2020年1月—2021年10月采集河南省43例COVID-19确诊病例的86份血清标本，46名灭活疫苗接种者的184份血清标本，50名未感染健康人的50份血清标本，采用磁微粒化学发光法和酶联免疫吸附法对320份血清标本检测并分析其抗体水平。 结果 确诊病例恢复期IgA、IgM、IgG抗体阳性率高于急性期（P值均 < 0.05）；恢复期的IgM、IgG抗体水平高于急性期（P值均 < 0.05）。灭活疫苗接种后31周，IgG和IgA抗体阳性率分别维持在63.04%（29/46）和36.96%（17/46），IgM抗体全部转阴；疫苗接种者第4、8、12、31周IgA抗体吸光度值差异无统计学意义（F = 2.365，P = 0.073），IgM、IgG抗体水平差异均有统计学意义（P < 0.05）。同时期确诊病例的IgA、IgM抗体阳性率高于疫苗接种者，IgM、IgG抗体水平高于疫苗接种者（P值均 < 0.05）。 结论 IgG抗体在新型冠状病毒感染早期和恢复期阳性率最高。IgA、IgG抗体出现时间较IgM早，在疫苗接种者体内持续时间超过31周。同时期确诊病例的IgM、IgG抗体水平高于疫苗接种者。
|
| 关 键 词： | IgA抗体 IgG抗体 IgM抗体 血清学检测 COVID-19确诊病例 新冠病毒灭活疫苗接种者 |
| 收稿时间： | 2022-08-05 |
| 修稿时间： | 2023-06-19 |
Evaluation of a new simultaneous anti-SARS-CoV-2 IgA,IgM and IgG screening automated assay based on native inactivated virus |
| |
| LI Dongxiao, LU Shidong, HU Xiao, SONG Yun, WU Bicong, LI Yafei, LI Yi, MA Hongxia, WANG Haifeng, YE Ying, HUANG Xueyong. Serum anti-SARS-CoV-2 IgA, IgM and IgG among confirmed COVID-19 cases at different stages and inactivated COVID-19 vaccine recipients after inoculation: a comparative analysis[J]. Chinese Journal of Public Health, 2023, 39(9): 1159-1164. DOI: 10.11847/zgggws1139954 |
| |
| Authors: | LI Dongxiao LU Shidong HU Xiao SONG Yun WU Bicong LI Yafei LI Yi MA Hongxia WANG Haifeng YE Ying HUANG Xueyong |
| |
| Affiliation: | 1.Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China |
| |
| Abstract: | Objective To examine time-dependent variations in serum antibodies of severe acute respiratory disease coronavirus 2 (SARS-CoV-2) among confirmed coronavirus disease 2019 (COVID-19) cases at different stages and inactivated COVID-19 vaccine recipients after inoculation. Methods The study was conducted in a city of Henan province. Totally 86 serum samples were collected from 43 confirmed COVID-19 cases at acute stage (1th – 23rd day of onset) and recovery state (25th – 58th day of onset) during January 2020 – October 2021; other 184 serum samples from 46 healthy recipients of inactivated COVID-19 vaccine at 4/8/12/31 weeks after inoculations and 50 serum samples from 50 residents without confirmed SARS-CoV-2 infections were also collected during March – October 2021. Anti-SARS-CoV-2 immunoglobulin A/G/M (IgA/G/M) were detected with magnetic particle chemiluminescence method and enzyme-linked immunosorbent assay for all the serum samples. The levels of the serum antibodies among the three groups′ participants were analyzed statistically. Results Among the confirmed COVID-19 cases, the positivity rates of anti-SARS-CoV-2 IgA, IgM and IgG of the serum samples collected at recovery stage were significantly higher than those at acute stage (all P < 0.05) ; while, the concentrations of anti-SARS-CoV-2 IgM and IgG of the serum samples collected at recovery stage were significantly higher than those at acute stage (both P < 0.05). Among the healthy COVID-19 vaccine recipients 31 weeks after the inoculations, the positivity rate was 63.04% (29/46) for anti-SARS-CoV-2 IgG and 36.96% (17/46) for anti-SARS-CoV-2 IgA, but all samples were negative for anti-SARS-CoV-2 IgM. No significant differences were observed in the absorbance ratios anti-SARS-CoV-2 IgA among the samples collected 4, 8, 12, and 31weeks after the inoculation (F = 2.365, P = 0.073), but there were significant differences in the concentrations of anti-SARS-CoV-2 IgM and IgG (both P < 0.05) among the samples. Both the positivity rate of anti-SARS-CoV-2 IgA and IgM and the concentrations of anti-SARS-CoV-2 IgG and IgM were significantly higher among the confirmed COVID-19 cases than those among the inactivated COVID-19 vaccine recipients during a comparable period of time (P < 0.05 for all). Conclusion The positivity rate of serum anti-SARS-CoV-2 IgG is the highest during early stage and recovery stage among COVID-19 cases. The positivity of serum anti-SARS-CoV-2 IgA and IgG occur earlier than that of IgM and could maintain till 31 weeks after the inoculation among inactivated COVID-19 vaccine recipients. The concentration of serum anti-SARS-CoV-2 IgG and IgM are higher among COVID-19 cases than those among inactivated COVID-19 vaccine recipients during a comparable period of time. |
| |
| Keywords: | IgA antibody IgG antibody IgM antibody serological detection COVID-19 cases inactivated COVID-19 vaccine recipients |
|
| 点击此处可从《中国公共卫生》浏览原始摘要信息 |
|
点击此处可从《中国公共卫生》下载全文 |
|
